# Circulating metabolic markers and risk of pancreatic cancer: a case-subcohort study

Christiana Kartsonaki

University of Oxford, United Kingdom

26 September 2024



#### Introduction

Pancreatic cancer has a very poor prognosis with 5-year survival of 5-10% and is often diagnosed late

Metabolic risk factors, such as adiposity and diabetes, and biomarkers, such as plasma glucose, fatty acids, and some proteins, have been shown to be associated with risk

Aimed to assess the associations between circulating metabolites and risk of pancreatic cancer



## Methods

Case-subcohort study on 681 incident pancreatic cancer cases and a subcohort of 892 individuals within the China Kadoorie Biobank, a prospective study of 512,891 adults

225 metabolic biomarkers measured in baseline plasma samples using nuclear magnetic resonance (NMR)

Cox regression fitted using the Prentice pseudo-partial likelihood, stratified by sex and region and adjusted for age, age<sup>2</sup>, time since last meal and its square, smoking status, alcohol consumption, educational attainment, diabetes, and body mass index, and time in study was used as the time scale



#### Associations with risk of pancreatic cancer

Several lipid-related biomarkers were associated with risk of pancreatic cancer, with adjusted HRs per 1-standard deviation increase in biomarker of 0.74 to 1.37

Glycoprotein acetyls and ratios of monounsaturated and of saturated fatty acids to total fatty acids were associated with a higher risk, while sphingomyelins, glutamine, estimated degree of unsaturation and ratios of omega-6 fatty acids and of polyunsaturated fatty acids to total fatty acids were associated with lower risk

The discriminatory ability of a model with known risk factors increased when several metabolic biomarkers were included (C-statistic 0.76 to 0.78)

#### Associations with risk of pancreatic cancer



UnSat: Estimated degree of unsaturation

XXL-VLDL-C %: Total cholesterol to total lipids ratio in chylomicrons and extremely large VLDL

XXL-VLDL-FC %: Free cholesterol to total lipids ratio in chylomicrons and extremely large VLDL

Gln: Glutamine

XXL-VLDL-TG %: Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL

PUFA/FA: Ratio of polyunsaturated fatty acids to total fatty acids

Gp: Glycoprotein acetyls, mainly a1-acid glycoprotein

XL-HDL-TG: Triglycerides in very large HDL

S-HDL-FC %: Free cholesterol to total lipids ratio in small HDL

XXL-VLDL-CE %: Cholesterol esters to total lipids ratio in chylomicrons and extremely large VLDL

S-VLDL-FC %: Free cholesterol to total lipids ratio in small VLDL

FAw6/FA: Ratio of omega-6 fatty acids to total fatty acids



#### Associations with short-term risk

Among pancreatic cancer cases, 47 (6.9%) were diagnosed within a year from baseline (and therefore of blood collection), 53 (7.8%) at 1 to less than 2 years, 217 (31.9%) were diagnosed 2 to less than 5 years and 364 (53.5%) were diagnosed 5 years or more after blood collection

Associations between some biomarkers and risk of pancreatic cancer were time-varying; for example fractions of medium and small HDL were inversely associated with short-term risk (within the first year of follow-up)

Within the first year, discriminatory ability substantially increased when including metabolic biomarkers (C-statistic 0.88 to 0.94)



#### Associations with short-term risk

1ct yoa

	ist year		Zild year	
Chylomicrons and extremely large VI DI		Hazard Ratio (95% CI)		Hazard Ratio (95% CI
Phospholipids to total lipids ratio		0.76 (0.57, 1.00)		0.88 (0.66, 1.17)
Very large VLDL Phospholipids to total lipids ratio Free cholesterol to total lipids ratio	<u> </u>	0.68 (0.54, 0.85) 0.67 (0.51, 0.88)		0.85 (0.65, 1.13) 1.35 (1.13, 1.61)
Large VLDL Free cholesterol to total lipids ratio		0.75 (0.58, 0.99)		1.05 (0.75, 1.46)
IDL Total cholesterol to total lipids ratio Cholesterol esters to total lipids ratio Triglycerides to total lipids ratio	 	0.75 (0.59, 0.97) 0.63 (0.47, 0.84) 1.33 (1.04, 1.71)		1.62 (1.14, 2.29) 1.48 (1.11, 1.96) 0.73 (0.52, 1.03)
Large LDL Cholesterol esters to total lipids ratio Triglycerides to total lipids ratio		0.77 (0.59, 0.99) 1.35 (1.07, 1.71)		1.31 (0.97, 1.78) 0.86 (0.62, 1.19)
Medium LDL Triglycerides to total lipids ratio	_ <b></b>	1.31 (1.04, 1.65)	<b>-</b> _	0.85 (0.62, 1.16)
Very large HDL Phospholipids to total lipids ratio Total cholesterol to total lipids ratio Cholesterol esters to total lipids ratio	<u> </u>	1.56 (1.13, 2.13) 0.66 (0.50, 0.88) 0.63 (0.45, 0.87)		0.83 (0.63, 1.09) 1.24 (0.88, 1.73) 1.17 (0.84, 1.62)
Medium HDL Concentration Total lipids Phospholipids Total cholesterol Cholesterol esters Free cholesterol Phospholipids to total lipids ratio Total cholesterol to total lipids ratio Cholesterol esters to total lipids ratio		$\begin{array}{c} 0.57 & (0.39, 0.83) \\ 0.57 & (0.39, 0.83) \\ 0.61 & (0.42, 0.89) \\ 0.56 & (0.38, 0.81) \\ 0.55 & (0.37, 0.79) \\ 0.63 & (0.44, 0.90) \\ - & 2.16 & (1.44, 3.23) \\ 0.67 & (0.47, 0.94) \\ 0.65 & (0.44, 0.96) \end{array}$		0.94 (0.71, 1.26) 0.95 (0.71, 1.27) 0.98 (0.73, 1.32) 0.93 (0.69, 1.27) 0.91 (0.67, 1.24) 1.02 (0.75, 1.37) 1.27 (0.92, 1.76) 0.89 (0.65, 1.22) 0.83 (0.62, 1.10)
Small HDL Concentration Total lipids Phospholipids Free cholesterol		0.65 (0.47, 0.88) 0.64 (0.47, 0.88) 0.59 (0.42, 0.82) 0.59 (0.42, 0.83)		0.81 (0.61, 1.07) 0.82 (0.62, 1.09) 0.79 (0.59, 1.05) 0.94 (0.69, 1.27)
Particle diameter Mean diameter for VLDL particles Mean diameter for LDL particles	<b></b>	0.74 (0.55, 0.99) 1.40 (1.05, 1.87)		0.85 (0.63, 1.14) 1.20 (0.90, 1.59)
Other Citrate Alanine Glutamine Histidine Creatinine		1.50 (1.12, 2.02) 0.70 (0.52, 0.95) 0.57 (0.38, 0.85) 0.69 (0.50, 0.94) 1.59 (1.07, 2.36)		1.16 (0.88, 1.54) 1.08 (0.79, 1.49) 0.53 (0.38, 0.75) 0.90 (0.66, 1.23) 0.38 (0.21, 0.72)
Fatty acids and measures of saturation Ratio of omega-3 fatty acids to total fatty acids		0.67 (0.48, 0.93)		1.05 (0.75, 1.46)
0.25	0.50 1.00 2.00	4.00	0.25 0.50 1.00 2.00	4.00
	Hazard Ratio (95% CI)	vectored.	Hazard Ratio (95% CI)	

2nd year



# Discussion

Several metabolic blood biomarkers were associated with short- and long-term risk of pancreatic cancer and may be useful to incorporate in strategies for prevention and earlier diagnosis

Our findings may provide insights into the pathophysiology of pancreatic cancer and future studies are needed to understand the role of these metabolic biomarkers in pancreatic cancer development



## Acknowledgements

Derrick Bennett, Zhengming Chen, Iona Millwood; China Kadoorie Biobank Collaborative Group

Pancreatic Cancer UK Research Innovation Fund

